Skip to content
Biodatica
Start free

Cellectar Biosciences, Inc.

Jacksonville, Florida

OncologyPhase IIListed · CLRB

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

6w agoTrial registeredJun 3, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Dec 5, 2025

    Breast Cancer · RECRUITING · sponsor: Cellectar Biosciences, Inc. · Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

    ClinicalTrials.gov · NCT07311993 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Oct 1, 2023

    High-Grade Glioma · ACTIVE_NOT_RECRUITING · sponsor: Cellectar Biosciences, Inc. · Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

    ClinicalTrials.gov · NCT05610891 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Apr 30, 2019

    Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma · ACTIVE_NOT_RECRUITING · sponsor: Cellectar Biosciences, Inc. · Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

    ClinicalTrials.gov · NCT03478462 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jul 26, 2017

    Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Cellectar Biosciences, Inc. · Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

    ClinicalTrials.gov · NCT02952508 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources